Agile Therapeutics Inc (AGRX)
0.3795
0.00 (0.00%)
USD |
OTCM |
May 15, 13:59
Agile Therapeutics Revenue (Quarterly): 3.614M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.614M |
| September 30, 2023 | 6.662M |
| June 30, 2023 | 5.503M |
| March 31, 2023 | 3.813M |
| December 31, 2022 | 3.996M |
| September 30, 2022 | 3.002M |
| June 30, 2022 | 2.126M |
| Date | Value |
|---|---|
| March 31, 2022 | 1.761M |
| December 31, 2021 | 1.514M |
| September 30, 2021 | 1.287M |
| June 30, 2021 | 1.185M |
| March 31, 2021 | 0.116M |
| December 31, 2020 | 0.749M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.116M
Minimum
Mar 2021
6.662M
Maximum
Sep 2023
2.718M
Average
2.126M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| Altimmune Inc | 0.037M |
| iBio Inc | -- |
| Verastem Inc | -- |
| Oragenics Inc | -- |
| Actinium Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -4.47M |
| Total Expenses (Quarterly) | 7.666M |
| EPS Diluted (Quarterly) | -1.41 |
| Enterprise Value | 1.739M |
| Gross Profit Margin (Quarterly) | 39.37% |
| Profit Margin (Quarterly) | -123.7% |
| Earnings Yield | -2.57K% |
| Normalized Earnings Yield | -3606.48 |